Skip links

Author: oncologs.com

oncotarget-welcomes-new-editorial-board-members

Oncotarget welcomes new editorial board members

BUFFALO, NY – July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry. Joining Dr. El-Deiry on Oncotarget’s Editorial Board are Dr. Trever Bivona, Dr. Phillip Buckhaults, Dr. Fred Bunz, Dr. Jonathan Chernoff,
improving-the-design-of-mrna-loaded-nanocarriers-for-targeted-therapies

Improving the design of mRNA-loaded nanocarriers for targeted therapies

Among the vastly different ways of tackling a disease, controlling the genetic expression of cells is undoubtedly one of the most powerful. Over the past few decades, scientists have come up with dozens of innovative strategies that involve using messenger RNA (mRNA) to ‘force’ cells
ddx41-and-its-unique-contribution-to-myeloid-leukemogenesis

DDX41 and its unique contribution to myeloid leukemogenesis

“[…] myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.” Credit: 2024 Matsui. “[…] myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.”
long-term-results-from-testicular-cancer-treatment-are-positive,-study-shows

Long-term results from Testicular Cancer treatment are positive, study shows

A new study shows that by combining different chemotherapy drugs, testicular cancer remains highly treatable and often curable, even after first-line treatment fails.  .  Credit: UCC A new study shows that by combining different chemotherapy drugs, testicular cancer remains highly treatable and often curable, even after
Explore
Drag